这不是上周的消息么，_老虎社区_美港股上老虎 - 老虎社区

点赞
评论
收藏

杭州小别墅
08-31 21:09

这不是上周的消息么，又他么扯淡到今天的下跌

异动解读｜Moderna盘前下跌3.25%，可转债发行稀释担忧叠加BioNTech同类疫苗失败拖累板块

8月31日，Moderna盘前下跌3.25%，报133.5美元/股，成交额1525.89万美元。与此同时，同行BioNTech的癌症疫苗近日宣告临床挫败，与Moderna此前mRNA癌症疫苗三期试验成功形成鲜明对比，但仍对整体医药板块情绪构成拖累。此外，尽管Argus Research近日将Moderna评级上调至买入并给出180美元目标价，华尔街整体仍以持有评级为主，市场对癌症疫苗商业化前景尚未形成一致共识，短期股价仍处于剧烈波动的价格重估阶段。

异动解读｜Moderna盘前下跌3.25%，可转债发行稀释担忧叠加BioNTech同类疫苗失败拖累板块

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

点赞

举报

评论

推荐
最新

empty

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":602735043653632,"tweetId":"602735043653632","gmtCreate":1788181752288,"gmtModify":1788182374274,"author":{"id":3567127559752478,"idStr":"3567127559752478","authorId":3567127559752478,"authorIdStr":"3567127559752478","name":"杭州小别墅","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":9,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p>这不是上周的消息么，又他么扯淡到今天的下跌</p></body></html>","htmlText":"<html><head></head><body><p>这不是上周的消息么，又他么扯淡到今天的下跌</p></body></html>","text":"这不是上周的消息么，又他么扯淡到今天的下跌","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/602735043653632","repostId":1189673025,"repostType":2,"repost":{"id":"1189673025","kind":"news","weMediaInfo":{"introduction":"个股异动一手消息解读","home_visible":1,"media_name":"行情直击","id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"pubTimestamp":1788180905,"share":"https://www.laohunote.com/m/news/1189673025?lang=zh_CN&edition=full","pubTime":"2026-08-31 20:55","market":"us","language":"zh","title":"异动解读｜Moderna盘前下跌3.25%，可转债发行稀释担忧叠加BioNTech同类疫苗失败拖累板块","url":"https://stock-news.laohu8.com/highlight/detail?id=1189673025","media":"行情直击","summary":"8月31日，Moderna盘前下跌3.25%，报133.5美元/股，成交额1525.89万美元。与此同时，同行BioNTech的癌症疫苗近日宣告临床挫败，与Moderna此前mRNA癌症疫苗三期试验成功形成鲜明对比，但仍对整体医药板块情绪构成拖累。此外，尽管Argus Research近日将Moderna评级上调至买入并给出180美元目标价，华尔街整体仍以持有评级为主，市场对癌症疫苗商业化前景尚未形成一致共识，短期股价仍处于剧烈波动的价格重估阶段。","content":"<p><p>8月31日，Moderna盘前下跌3.25%，报133.5美元/股，成交额1525.89万美元。消息面上，公司此前将2032年到期零息可转换高级债券发行规模从20亿美元上调至26亿美元，并授予初始购买者额外认购最多4亿美元票据的选择权，股权稀释担忧持续压制股价，该股上一交易日已收跌3.35%。</p><p>与此同时，同行BioNTech的癌症疫苗近日宣告临床挫败，与Moderna此前mRNA癌症疫苗三期试验成功形成鲜明对比，但仍对整体医药板块情绪构成拖累。此外，尽管Argus Research近日将Moderna评级上调至买入并给出180美元目标价，华尔街整体仍以持有评级为主，市场对癌症疫苗商业化前景尚未形成一致共识，短期股价仍处于剧烈波动的价格重估阶段。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜Moderna盘前下跌3.25%，可转债发行稀释担忧叠加BioNTech同类疫苗失败拖累板块</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜Moderna盘前下跌3.25%，可转债发行稀释担忧叠加BioNTech同类疫苗失败拖累板块\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1059448697\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">行情直击 </p>\n<p class=\"h-time\">2026-08-31 20:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>8月31日，Moderna盘前下跌3.25%，报133.5美元/股，成交额1525.89万美元。消息面上，公司此前将2032年到期零息可转换高级债券发行规模从20亿美元上调至26亿美元，并授予初始购买者额外认购最多4亿美元票据的选择权，股权稀释担忧持续压制股价，该股上一交易日已收跌3.35%。</p><p>与此同时，同行BioNTech的癌症疫苗近日宣告临床挫败，与Moderna此前mRNA癌症疫苗三期试验成功形成鲜明对比，但仍对整体医药板块情绪构成拖累。此外，尽管Argus Research近日将Moderna评级上调至买入并给出180美元目标价，华尔街整体仍以持有评级为主，市场对癌症疫苗商业化前景尚未形成一致共识，短期股价仍处于剧烈波动的价格重估阶段。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189673025","content_text":"8月31日，Moderna盘前下跌3.25%，报133.5美元/股，成交额1525.89万美元。消息面上，公司此前将2032年到期零息可转换高级债券发行规模从20亿美元上调至26亿美元，并授予初始购买者额外认购最多4亿美元票据的选择权，股权稀释担忧持续压制股价，该股上一交易日已收跌3.35%。与此同时，同行BioNTech的癌症疫苗近日宣告临床挫败，与Moderna此前mRNA癌症疫苗三期试验成功形成鲜明对比，但仍对整体医药板块情绪构成拖累。此外，尽管Argus Research近日将Moderna评级上调至买入并给出180美元目标价，华尔街整体仍以持有评级为主，市场对癌症疫苗商业化前景尚未形成一致共识，短期股价仍处于剧烈波动的价格重估阶段。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","news_type":1,"symbols_score_info":{"MRNA":1}},"isVote":1,"tweetType":1,"viewCount":0,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":41,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}